𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score–based liver allocation system

✍ Scribed by Claire Francoz; Jacques Belghiti; Denis Castaing; Olivier Chazouillères; Jean-Charles Duclos-Vallée; Christophe Duvoux; Jan Lerut; Yves-Patrice Le Treut; Richard Moreau; Ameet Mandot; Georges Pageaux; Didier Samuel; Dominique Thabut; Dominique Valla; François Durand


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
437 KB
Volume
17
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


Model for End-Stage Liver Disease (MELD) score-based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis. Except for extreme values, high pretransplant MELD scores do not significantly affect posttransplant survival. The MELD score can be used to optimize the allocation of allografts according to a sickest first policy. Most often, patients with small hepatocellular carcinomas (HCCs) and low MELD scores receive extra points, which allow them appropriate access to transplantation comparable to the access of patients with advanced cirrhosis and high MELD scores. In addition to patients with advanced cirrhosis and HCC, patients with a number of relatively uncommon conditions have low MELD scores and a poor prognosis in the short term without transplantation but derive excellent benefits from transplantation. These conditions, which correspond to the so-called MELD score exceptions, justify the allocation of a specific score for appropriate access to transplantation. Here we report the conclusions of the French consensus meeting. The goals of this meeting were (1) to identify which conditions merit MELD score exceptions, (2) to list the criteria needed for defining each of these conditions, and (3) to define a reasonable time interval for organ allocation for each MELD exception in the general context of organ shortages. MELD exceptions were discussed in an attempt to reconcile the concepts of transparency, equity, justice, and utility.


📜 SIMILAR VOLUMES


Model for end-stage liver disease (MELD)
✍ Luis Arrazola; Dilip Moonka; Robert G. Gish; Gregory T. Everson 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Polycystic liver disease (PLD) is commonly associated with polycystic kidney disease, but is unaccompanied by renal cysts in 10% of cases. Symptomatic PLD is mainly limited to adults and rarely, if ever, presents in childhood. There is currently no effective medical therapy for PLD. Most patients wh

Clinically relevant differences in the M
✍ Rhiana Garritsen; Andrei Tintu; Herold Metselaar; Geert Kazemier 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views

With interest, we read the article by Xiol et al. 1 regarding differences in serum measurements between different laboratories and their influence on the Model for End-Stage Liver Disease (MELD) and the Model for End-Stage Liver Disease incorporating serum sodium (MELD-Na). They reported significant

Reply: Clinically relevant differences i
✍ Xavier Xiol; Jose Castellote; Xavier Fuentes-Arderiu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 37 KB 👁 1 views

We thank Garritsen et al. 1 for their interest in our article about differences in Model for End-Stage Liver Disease (MELD) and Model for End-Stage Liver Disease-Sodium (MELD-Na) scores determined at 3 different laboratories. 2 We agree that one of the important messages of our article is the import